Tag:
AMRI
Latest Headlines
Latest Headlines
AMRI piles on profits with strong Q2
AMRI's days of posting quarterly net losses appear to be far behind, as the company rode an 11% revenue jump to $6.5 million in net income, up from a negative $3.8 million in the same period last year.
AMRI inks 5-year CDMO deal with Ono
AMRI has locked down another 5-year partnership with Japan's Ono Pharmaceutical, agreeing to provide development and manufacturing services for the company's treatments, which include a promising multiple sclerosis drug.
AMRI 'money pit' now moneymaker
When contract development and manufacturer Albany Molecular Research (AMRI) bought out Hyaluron in 2010, it picked up a headache in the process. The FDA found significant problems at the former Hyaluron plant in Burlington, MA, and issued it a warning letter. That was then.
With revenue rolling, AMRI looks to CDMO boom in 2013
AMRI's contract development and manufacturing business soared by 50% in the fourth quarter, and the New York outsourcer sees no sign of slowdown, projecting more growth in 2013.
AMRI re-ups with GE Healthcare, its largest supply partner
Amid budget-slashing and restructuring, AMRI has some good news to report: The CRO has re-signed with GE Healthcare to supply materials for diagnostic imaging, locking down its biggest commercial supply client through 2016.
AMRI shutters R&D site, moving jobs to Singapore
The Bothell plant employs 24 people, AMRI said in a statement, and the cost-cutting measure is designed to "address and anticipate changes in the marketplace," according to the company.
AMRI shutters R&D site, moving jobs to Singapore
CRO AMRI is closing up its R&D shop in Bothell, WA, and shipping the site's biology capabilities to its drug discovery operation in Singapore.
AMRI narrows losses on strong Q3
CMO AMRI posted an 11% jump in revenue in the third quarter, cutting its net loss by about $3.8 million thanks to double-digit growth in large-scale manufacturing.
BIO 2012: In-sourcing, outsourcing drive AMRI's 'SmartSourcing'
According to AMRI, SmartSourcing can use services from its global facilities, insource their own experts and communicate better with clients.
AMRI sees Q1 drops, but maintains positive financial outlook for 2012
As Albany Molecular Research ($AMRI) progresses into 2012, it is driven to recoup revenue it lost out on in the first quarter.
